Pliant Therapeutics (PLRX) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 11, 2026, at 8:30 a.m. Pacific Time, to be held virtually.

• Shareholders are encouraged to review proxy materials and vote by June 10, 2026.

Voting matters and shareholder proposals

• Election of three class III directors: Bernard Coulie, Gayle Crowell, and Steve Krognes.

• Advisory vote on approval of Named Executive Officer compensation.

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.

• Proxies may vote on other business as may properly come before the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all director nominees and proposals.